investor-relations

RMD

NYSE: 85.70 +0.41 +0.48% Volume: 487,307 December 18, 2017
ASX: Volume:
$2.1 Billion
fiscal year 2017


10%
Adjusted EPS growth over the last five fiscal years

77%
free cash flow returned to shareholders over the last rolling five years

About ResMed

ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company with more than 4 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries.

Learn more 2015 Investor Day ResMed Respiratory Medicine 101  

Email Alerts

Email Adress Email Address: *
Mailing Lists *





 
Enter the code shown above.